In a patient on warfarin who has a subdural hematoma, is this considered a history of intracranial hemorrhage?

Yes, subdural hematoma is absolutely considered a history of intracranial hemorrhage.

A subdural hematoma (SDH) is definitively a type of intracranial hemorrhage and should be treated as such when making decisions about warfarin management. This classification has critical implications for your patient's anticoagulation strategy going forward.

Why This Matters for Warfarin Management

The evidence consistently categorizes subdural hematomas within the broader category of intracranial hemorrhage (ICH) when discussing anticoagulation decisions 1. Multiple guidelines specifically address "warfarin-associated ICH" and include both spontaneous intracerebral hemorrhages and traumatic subdural hematomas in their recommendations 1, 2.

Key Clinical Implications:

Restarting warfarin after subdural hematoma carries significant risk. The data shows:

• Patients who resume warfarin after any intracranial hemorrhage have a hazard ratio of 5.6 (95% CI, 1.8–17.2) for recurrent ICH 1
• In one study of warfarin-associated ICH patients who restarted anticoagulation, 1 had recurrent ICH and 2 had subsequent traumatic intracranial hemorrhage 1
• However, patients who don't restart face thromboembolism risk—in the same study, 5 patients who didn't restart developed thromboembolism (2 with stroke) 1

Timing Considerations for Warfarin Resumption

The most recent guidelines recommend delaying warfarin resumption for at least 4 weeks after intracranial hemorrhage in patients without high thrombotic risk 3. The 2025 French guidelines specifically state this 4-week minimum based on studies showing increased hemorrhage risk before 4-8 weeks 3.

For patients with high thrombotic risk (like mechanical heart valves), the decision becomes more nuanced:

• Some data suggest considering resumption as early as 6 days in very high-risk patients 3
• The 2015 AHA/ASA guidelines suggested 7-10 days for very high thromboembolic risk 4, 5
• A survival model found optimal timing around 10 weeks when balancing both risks 1

Risk Stratification Matters:

The location and mechanism of the subdural hematoma influences decision-making:

• Traumatic SDH: Research shows 40% of intracranial hemorrhages in anticoagulated AF patients are traumatic, with 64% being subdural hematomas 6
• Spontaneous vs. traumatic: While traumatic SDH has lower 30-day mortality (25% vs 36% for spontaneous ICH), both carry recurrence risk with warfarin 6
• The mechanism (traumatic vs spontaneous) should be documented but doesn't eliminate the classification as intracranial hemorrhage

Practical Algorithm for Your Patient:

1. Immediately: Subdural hematoma = history of intracranial hemorrhage for documentation purposes

2. Assess thrombotic risk:

   • Mechanical valve? → Very high risk, consider earlier resumption (6 days to 4 weeks with multidisciplinary discussion) 3
   • Atrial fibrillation without prior stroke? → Lower risk, delay ≥4 weeks 3
   • Prior stroke/TIA with AF? → Intermediate risk, consider alternatives to warfarin

3. Consider alternatives:

   • Antiplatelet therapy may be safer than warfarin for lower-risk patients 1, 4
   • Left atrial appendage closure for AF patients with contraindication to anticoagulation 3
   • DOACs may have lower ICH risk than warfarin, though data after ICH is limited 1

4. If resuming warfarin:

   • Wait minimum 4 weeks for standard risk 3
   • Ensure source of bleeding identified and treated 3
   • Consider imaging for microbleeds (increases recurrence risk) 1

Common Pitfalls to Avoid:

• Don't dismiss traumatic SDH as "less serious" for anticoagulation decisions—it still represents intracranial hemorrhage with recurrence risk
• Don't restart warfarin before 4 weeks without compelling high-risk indication and multidisciplinary discussion
• Don't assume the patient needs warfarin resumed—carefully reassess the indication and consider alternatives
• Don't forget to document this as "history of intracranial hemorrhage" in the medical record, as it affects future anticoagulation decisions

The evidence is clear: subdural hematoma, whether traumatic or spontaneous, is intracranial hemorrhage and fundamentally changes your patient's risk-benefit calculation for warfarin therapy 1, 2, 3, 1, 6.